news tirzepatide SURPASS-CVOT: Significantly Reduces Major Kidney Events Compared to Dulaglutide in T2D Kidney Outcomes in SURPASS: Exploring

Its triple-receptor action may provide more comprehensive effects than single-target medications

The likelihood of GLP-1 success Five out of six major pooled analyses suggest GLP-1s significantly lower the risk of dementia and Alzheimers

Pair that with whole-food meals rich in plants, fiber and lean proteins for the best long-term results

2020 Mar;52(2):e13470

Possible side effects include: Mild pain, redness, or swelling at the injection site Headache or dizziness (usually transient) Nausea (uncommon) Hypokalaemia (low potassium) during initial treatment, particularly in severely deficient patientsthis is rare but may require monitoring [1] [5] When to seek medical advice: Serious adverse reactions are extremely rare